Actinium Pharmaceuticals (ATNM) is a clinical-stage biopharmaceutical company. CEO Sandesh Seth discusses ATNM which is developing a new radiotherapy candidate for cancer patients. The company released promising results from trials of its radiotherapy candidate IOMAB-B which could help patients with relapsed or refractory acute myeloid leukemia receive bone marrow transplants. He then goes over the outlook for the company. Tune in to find out more about the stock market today.
14 Nov 2022
Morning Trade Live
15 Sep 2023
Market On Close
09 Nov 2023
Market On Close
24 Oct 2023
The Watch List
21 Sep 2023
Trading 360
09 Nov 2023
Morning Trade Live
08 Sep 2023
Current show
Mon—Fri at 10:00 am — 11:00 am
Trading 360